BullFrog AI is at the forefront of a transformative wave in the biopharma industry, thanks to its proprietary bfLEAP™ platform. This innovative platform is not just an award-winning technological marvel with over 200 algorithms and functions; it is a beacon of hope in a sector where only 12% of drugs successfully transition from clinical trials to market. The bfLEAP™ platform is uniquely equipped to discover novel drug targets and predict the profile of patients most likely to respond to therapies under development, positioning BullFrog AI to potentially revolutionize drug discovery and development by significantly reducing time, costs and failure rates. Importantly, BullFrog AI’s exclusive partnership with the Lieber Institute for Brain Development, which maintains the largest and most comprehensive human neuropsychiatric brain database in the world, provides a strong competitive edge in targeting companies focused on the development of central nervous system disorder drugs. The CNS therapeutics market was estimated at $117 billion in 2022 and is expected to surpass $140 billion by the end of 2026.

Another compelling aspect for investors is BullFrog AI's operational model. With a lean team and low overhead expenses, the company exemplifies efficiency and agility. This operational efficiency, coupled with its current market capitalization, presents a uniquely attractive investment opportunity. The potential for significant upside in this rapidly evolving market cannot be overstated, especially considering BullFrog AI's float of 2.8 million shares and the high-value transactions characteristic of its sector.

Further bolstering BullFrog AI's position is the extension of its bfLEAP™ platform through BullFrog Data Networks. These networks are designed to weave together comprehensive data from various sources – including clinical trial data, EMR, claims, -omics, and Real-World Data (RWD) – using unsupervised machine learning. This approach is not just about data aggregation; it's about uncovering hidden insights that could be pivotal in accelerating drug development.

BullFrog AI's near-term objectives are equally promising. The company's aggressive pursuit of business opportunities, expansion of its technical team, active promotion among investors and biopharma customers, and search for strategic R&D partners highlight its proactive and ambitious approach. Current partnerships with prestigious institutions like Johns Hopkins University and J. Craig Venter Institute, alongside the Lieber Institute, further affirm its credibility and potential.

In summary, BullFrog AI represents an extraordinary investment opportunity at the intersection of technology and healthcare. Its innovative approach, strategic partnerships, operational efficiency, and promising market position make it a beacon of potential in the quest to reshape the industry and usher in a new era of precision medicine. The future shines bright for BullFrog AI, with its unique blend of cutting-edge technology, strategic collaborations, and a market-ready operational model.

• Exclusive Licensing Deals with Leading Research Institutions
  • Discovery phase liver cancer drug candidate siRNA; hepatocellular carcinoma market size was $1.0 billion in 2019, expected to grow at 17.8% CAGR by 2029
  • Phase 2 ready brain cancer drug candidate Mebendazole and prodrug; glioblastoma market size was $2.1 billion in 2020, expected to grow at 8.8% CAGR between 2021-2028
  • Exclusive partnership with the Lieber Institute provides a strong competitive edge in targeting companies focused on the development of central nervous system disorder drugs; CNS therapeutics market ~$117 billion in 2022 and expected to surpass $140 billion in 2026
  • Discovery phase oncolytic virus program with J Craig Venter Institute
• Proprietary bfLEAP™ AI Platform
  • Scalable data analytics — able to analyze big data and “short and wide” data sets
  • Unsupervised AI/ML platform has ability to make predictions with incomplete data and reveal meaningful insights without a pre-existing hypothesis
  • Proprietary clustering algorithms find non-linear, multi-variate relationships in large, highly complex data sets; outperforms the currently used top 10 clustering algorithms for data analysis
  • bfLEAP™’s Prometheus/Euclid/Seagull algorithm suite selected as finalist for the R&D 100 Awards
• Successful Schizophrenia Case Study
  • Using bfLEAP™, analyzed CATIE trial data — the largest clinical study ever conducted for anti-psychotic drugs; identified novel correlations between study outcomes and genetic loci for all medications
  • Four medications, 200 patients per medication, 200 non-genetic attributes (race, smoking, drug clearance, etc.), and 750,000 genetic attributes from single nucleotide polymorphism profiles
• Accomplished Leadership Team
  • Vin Singh, Founder & CEO; extensive knowledge in electrical and biomedical engineering. Former CEO of Next Healthcare Inc and co-founder of MaxCyte
  • Dane Saglio, CFO; seasoned executive with in-depth experience in finance and accounting. Former CFO of EntreMed, Inc., New Generation Biofuels, Inc., and RegeneRx Biopharmaceuticals, Inc.

RedChip Investor Group Call with BullFrog AI (NASDAQ: BFRG)

Date: Tuesday, March 5, 2024

Watch Replay Now